Seroconversion of IgG anti- human papillomavirus (HPV) serotypes 6, 11, 16 and 18 at months 7 and 12 after vaccination
| Month 7 | Month 12 | |||||
|---|---|---|---|---|---|---|
| HPV type | Patients with SLE | Controls | p Value | Patients with SLE | Controls | p Value |
| 6 | 29/39 (74%) | 43/45 (96%) | 0.01 | 32/39 (82%) | 44/45 (98%) | 0.02 |
| 11 | 29/38 (76%) | 42/44 (95%) | 0.02 | 34/38 (89%) | 43/44 (98%) | 0.18 |
| 16 | 36/39 (92%) | 43/44 (98%) | 0.34 | 37/39 (95%) | 43/44 (98%) | 0.60 |
| 18 | 29/38 (76%) | 37/40 (93%) | 0.06 | 29/38 (76%) | 32/40 (80%) | 0.69 |
SLE, systemic lupus erythematosus.